Windlas Biotech Ltd.

₹754.35

22.9 (3.1%)

WINDLAS Share Price

Pharmaceuticals & Biotechnology

As on March 10, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 1,599 Cr

P/E Ratio25.92

Dividend Yield0.15 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	747.99	Bullish
10-DMA	753.15	Bullish
20-DMA	773.47	Bearish
50-DMA	793.37	Bearish
100-DMA	815.58	Bearish
200-DMA	880.46	Bearish

Historical Performance

1 Year

-17.7%

3 Years

198.8%

5 Years

N/A

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	7,599	6,310	5,131	4,659	4,276
Total Expenditure	6,658	5,528	4,529	4,135	3,729
Other Income	180	135	100	67	31
Operating Profit	1,121	916	702	591	578
Interest	44	11	8	14	13
Depreciation	280	134	124	121	130
Profit Before Tax	798	771	570	456	217
Consolidated Net Profit	610	582	426	381	158
Adjusted EPS	29	28	20	17	9

Compounded Sales Growth

10 Years:16.6

5 Years:18.2

3 Years:10.3

TTM:3.8

Compounded Profit Growth

10 Years:40.4

5 Years:30.3

3 Years:9.9

TTM:0.9

Stock Price CAGR

10 Years:N/A

5 Years:N/A

3 Years:44

TTM:-19.2

Return on Equity

10 Years:N/A

5 Years:8.7

3 Years:20.4

last year:29.1

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	105	104	105	109	64
Total Reserves	4,900	4,346	3,890	3,821	1,927
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	50	39	34	2	36
Other Current Liabilities	535	395	325	251	238
Short Term Borrowings	271	---	---	53	294
Total Liabilities	7,602	6,256	5,270	4,890	2,961
Capital Work in Progress	32	57	138	76	---
Long Term Loans & Advances	52	75	433	54	58
Currents Investments	2,234	1,734	1,065	648	231
Short Term Loans and Advances	359	268	287	304	167
Total Current Assets	5,251	4,313	3,535	3,817	1,943
Total Assets	7,602	6,256	5,270	4,890	2,961
Adjusted Book Value	239	214	191	180	109

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 25.92, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 44.4%, indicating sustained price appreciation.
The stock carries a beta of 1.0, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹1121 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹7599 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 807655.2

No. of Shares: 1071 (Approx)

Performance:-19.2%

P/L: ₹-192344.8

NIFTY Performance: 7.8%

1 day Top Gainers